Inhibition of RFWD3 activates the IFN pathway to enhance the innate immune response, suggesting that targeting RFWD3 could convert immunosuppressive “cold” tumors into immunoreactive “hot” tumors to improve the tumor response to ICI therapy. This evidence concerns the gene IFNA1 and neoplasm.